INTRODUCTION AND OBJECTIVES: Multi-parametric magnetic resonance imaging (mp-MRI) based prostate imaging reporting and data system (PIRADS) is limited in confidently and robustly distinguishing clinically significant and insignificant prostate cancer (PCa). Radiomic features employ image processing methods to characterize specific patterns in images and have been shown to better characterize PCa than mp-MRI signal intensities alone. For example, gradient features quantify the appearance of edges, Haralick features distinguish homogenous low intensity (PCa) from normal regions and Gabor features quantify appearance of PCa at multiple orientations and scales. In this study, we aim to identify which of the mp-MRI derived radiomic features can distinguish high and low risk PCa as defined by the D'Amico criteria.
INTRODUCTION AND OBJECTIVES: Multi-parametric magnetic resonance imaging (mp-MRI) based prostate imaging reporting and data system (PIRADS) is limited in confidently and robustly distinguishing clinically significant and insignificant prostate cancer (PCa). Radiomic features employ image processing methods to characterize specific patterns in images and have been shown to better characterize PCa than mp-MRI signal intensities alone. For example, gradient features quantify the appearance of edges, Haralick features distinguish homogenous low intensity (PCa) from normal regions and Gabor features quantify appearance of PCa at multiple orientations and scales. In this study, we aim to identify which of the mp-MRI derived radiomic features can distinguish high and low risk PCa as defined by the D'Amico criteria.
METHODS: A retrospective cohort of 452 PCa patients who underwent a 3 Tesla mp-MRI scan was considered for this study. A subset of 72 patients comprising 153 lesions was chosen chronologically based on PIRADS to obtain a statistically balanced cohort. D'Amico criteria were available for 83 lesions and was used to categorize into low (N¼ 26), intermediate (N ¼ 43) and high (N ¼ 14) risk groups. A balanced dataset of N ¼ 28 lesions with 14 lesions from each of high and low risk categories was finally assembled for radiomic feature analysis.
RESULTS: A set of 101 radiomic features were extracted on a voxel-wise basis within the lesion region of interest (ROI) from each of T2w and ADC MRI sequences. First order statistics (mean, variance, skewness and kurtosis) were computed within each ROI to obtain 808 features per ROI. Of these, 44 features showed statistically significant differences between high and low risk lesions. Specifically, variance and skewness of T2w gradient and Gabor features, skewness and kurtosis of ADC Haralick and Laws features showed p<0.05 using Wilcoxon Rank-Sum test (representative results are shown in Figure) . A random forests classifier trained using these radiomic features within a 3-fold cross validation framework resulted in an AUC of 0.96. CONCLUSIONS: Radiomic features derived from mp-MRI distinguish high and low risk prostate cancer lesions as defined by D'Amico criteria. An independent validation of these features is required on a separate test set. 
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INTRODUCTION AND OBJECTIVES:
A multifaceted approach using commercially available prostate biomarkers to aid in the decision making for diagnosing and treating prostate cancer has taken place in recent years. We aim to determine if the 4K score and Michigan Prostate Score (MIPS) change cancer detection rates in PIRADS 3 or lower disease.
METHODS: A retrospective review of 58 consecutive patients who underwent multi-parametric magnetic resonance imaging (mpMRI) of the prostate, 4k score and MIPS test between December 2015 and September 2016 was performed. Indications for mpMRI, 4k score and MIPS test included an abnormal digital rectal examination, elevated PSA, PSA velocity > 0.75 ng/ml/year, and patients on active surveillance. All 3 tests were ordered during the same clinic visit prior to knowing the results of the other test. We excluded patients with PIRADS score 4 or 5. Clinically significant cancer was defined as GS ¼ 7.
RESULTS: A total of 17 patients (32 lesions) with PIRADS ¼ 3 and 4k score test underwent MRI/US guided fusion biopsy. Median PSA was 5.6 ng/ml (1st quartile: 4.49 ng/ml, 3rd quartile 10.14 ng/ml). Median age was 63.5 (1st quartile 57.5, 3rd quartile 67.25). Median 4k score was 21% (1st quartile 9%, 3rd quartile 62%). A total of 8 patients (47%) were diagnosed with prostate cancer. 7/8 patients (88%) had biopsies that were positive for clinically significant cancer (Grade group 2¼ 5) and 2/7 patients (29%) had high grade cancer GS¼8 (Grade group 4¼ 1, Grade group 5¼ 1). 5 patients had 4k scores > 60% and all 5 patients were diagnosed with clinically significant prostate cancer on same session sextant biopsy. 2 of the 5 (40%) of patients had cancer diagnosed on both mpMRI/US guided fusion and random sextant biopsy. 3 of the 5 patients (60%) did not have clinically significant prostate cancer on mpMRI/US guided fusion biopsy but had CaP on same session sextant biopsy (Table 1) , p < 0.001. There was no significant difference between the patients with high MIPS and MRI fusion biopsy cores or sextant biopsy cores, p ¼ 0.61.
CONCLUSIONS: The 4K score may be a useful adjunct to mpMRI of the prostate in patients with PIRADS ¼ 3. In this series, patients with high 4k score were found to have high grade prostate cancer on same session random prostate biopsy that was missed on mpMRI guided fusion biopsy.
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